- cafead   Jun 05, 2024 at 11:12: AM
via Vir Biotechnology's hepatitis D combination therapy has shown early efficacy in results from a phase 2 trial, suggesting the drug cocktail may pose a threat to Gilead Sciences' stuttering attempt to capture the market.
article source
article source